Maynard Um
-
-
-
-
-
-
-
FDA grants accelerated approval to Replimune's Tudriqev for melanoma
-
-
-
-
-
-
-
Replimune stock tumbles 20% after FDA raises efficacy concerns
-
-
-
-
-
-
-
Increasing unusual put volume: AS WEN REPL BHC BTG IGV HWM CHYM BURL CIA
-
-
-
-
-
-
-
Replimune plans RP1 cancer drug resubmission after FDA talks
-
-
-
-
-
-
-
Jefferies Downgrades Replimune Group (REPL) to Hold
-
-
-
-
-
-
-
Replimune (REPL) Halted on Volatility, Down 8%
-
-
-
-
-
-
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
466,312 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


